Document Detail


Midterm response with latanoprost therapy in german ocular hypertension patients.
MedLine Citation:
PMID:  17364735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The purpose of this prospective observational trial was to report the analysis of the midterm efficacy, safety, and discontinuation rates of a cohort of ocular hypertensive patients treated with latanoprost in Germany. METHODS: A subanalysis of patients with ocular hypertension who were previously treated on latanoprost monotherapy and continued within the study on this same medication for at least 6 months. RESULTS: 353 patients with ocular hypertension were included and treated with latanoprost monotherapy historically (1.4 +/- 1.3 years) and within the observational period of the study for a mean of 2.2 +/- 1.1 years. On latanoprost only, the average intraocular pressure at study entry was 18.4 +/- 2.7 mm Hg, and at 6 months the intraocular pressure was 18.3 +/- 2.3 mmHg (p = 0.54). During the observational period, the most common ocular side effect was conjunctival hyperemia (20.7%), and the most common systemic side effect was fatigue (3.1%). Nineteen patients (5.4%) discontinued latanoprost with the most common reason being insufficient efficacy (3.1%). Physician assessments of latanoprost monotherapy were "very good" to "excellent" for patient efficacy (75.2%), tolerability (83.8%), and patient satisfaction (82.1%). CONCLUSIONS: The study suggests that patients with ocular hypertension already treated with latanoprost monotherapy will continue to have, on average, at least midterm stable pressures, low incidence of side effects and discontinuations, as well as "very good" to "excellent" physician ratings of efficacy, tolerability, and patient satisfaction.
Authors:
Ulrich Thelen; Thomas Christ; Dietmar Schnober; Hans-Joachim Hofstetter; William C Stewart
Related Documents :
1420055 - Ocular circulatory changes following scleral buckling procedures.
7259595 - Fluorophotometric study of epinephrine and timolol in human subjects.
11272785 - Ockham's glaucoma.
7681195 - Anatomical and morphological evaluation of pacemaker lead compression.
2737495 - Correlation between pain thresholds and polysynaptic components of blink reflex in esse...
18823885 - Effects of adding small amounts of oxygen to a carbon dioxide-pneumoperitoneum of incre...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current eye research     Volume:  32     ISSN:  0271-3683     ISO Abbreviation:  Curr. Eye Res.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-03-16     Completed Date:  2007-03-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8104312     Medline TA:  Curr Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  51-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / adverse effects,  therapeutic use*
Female
Germany
Humans
Intraocular Pressure / drug effects
Male
Middle Aged
Ocular Hypertension / drug therapy*
Prospective Studies
Prostaglandins F, Synthetic / adverse effects,  therapeutic use*
Tonometry, Ocular
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Prostaglandins F, Synthetic; 130209-82-4/latanoprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Isolation, culture, and characterization of human fetal trabecular meshwork cells.
Next Document:  The effects of caspofungin and voriconazole in experimental Candida endophthalmitis.